company
High Liver Fat (Hepatic Steatosis) Linked to Increased Risk of Hospitalization in COVID-19 Patients with Obesity
March 29, 2021
LiverMultiScan shown to be the best non-invasive predictor of disease activity in autoimmune hepatitis, demonstrating its potential to influence clinical treatment.
March 3, 2021
Perspectum Lands Top Spot in Alantra Pharma Fast 50 Rankings
March 1, 2021
New research demonstrates superior performance of LiverMultiScan® for identifying patients with NASH and fibrosis
February 24, 2021
LiverMultiScan® could be an alternative to liver biopsy for NASH clinical trials.
February 4, 2021
UVA Health First Hospital in the State to Offer LiverMultiScan for Non-Invasive Assessment of Liver Disease
February 2, 2021
Perspectum launches study to improve outcomes for patients with liver cancer
January 14, 2021
World’s First Integrated Imaging Service for Long Covid approved by UK’s MHRA
FDA awards funding to Perspectum and physicians at Massachusetts General Hospital to accelerate development of imaging biomarkers as drug development tools in liver disease
December 14, 2020
